SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc. (AMEX: TTP) today announced completion of enrollment in the randomized, double-blind Phase IIb clinical study of Spheramine in the treatment of advanced Parkinson’s disease. A total of 71 patients were treated in the study. Spheramine is being developed by Titan in collaboration with Bayer Schering Pharma AG, Titan’s partner for worldwide development and commercialization of Spheramine. Results from the study are expected to be available in the third quarter of 2008.
